News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports 2019 Financial Results and Recent Operational Progress

April 28, 2020

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

April 16, 2020

Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

April 2, 2020

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

April 2, 2020

Affimed Announces Participation at Upcoming Virtual Investor Conferences

March 26, 2020

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

March 17, 2020

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

February 19, 2020

Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer

February 3, 2020

Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer

January 10, 2020

Affimed Announces Addition to NASDAQ Biotechnology Index

December 18, 2019

Events

All

Scientific

Investors

27Sep

2021 Cantor Fitzgerald Virtual Global Healthcare Conference

September 27 - 30, 2021 (Virtual)
Presenter: Adi Hoess

07Oct

AACR-NCI-EORTC

October 7 - 10, 2021 (virtual)

02Nov

PEGS Europe

November 2 - 4, 2021 (Barcelona, Spain)

Webcasts
More events